The Role of SGLT2 inhibitors in Management of Diabetes

Diabetes Mellitus is a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia, associated with disturbances in carbohydrate, fat, and protein metabolism. These abnormalities result from defects in insulin secretion, insulin action, or both.

Diabetes is a major global health problem and occurs throughout the world, with Type 2 Diabetes Mellitus being the most common form. Globally, hundreds of millions of adults are living with diabetes, and the burden is expected to continue rising. Type 2 Diabetes accounts for the majority of diabetes cases and is strongly associated with insulin resistance, obesity, reduced physical activity, and other metabolic risk factors.

In Uganda, diabetes remains an important non-communicable disease, with increasing relevance in routine clinical practice because of its long-term complications and its association with cardiovascular, renal, and metabolic disease.

Diabetes Mellitus can be classified into several major categories:

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Other specific types of diabetes
Gestational Diabetes Mellitus

Type 1 Diabetes Mellitus results primarily from destruction of pancreatic beta cells, usually leading to absolute insulin deficiency. This makes insulin necessary for survival. It may be immune-mediated or idiopathic.

Type 2 Diabetes Mellitus is the most common form of diabetes. It usually results from a combination of peripheral insulin resistance and progressive failure of pancreatic beta cells to produce enough insulin to overcome that resistance. In Type 2 Diabetes, patients usually have relative insulin deficiency rather than absolute insulin deficiency.

Gestational Diabetes Mellitus is defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy.

Clinical Stages of Diabetes Mellitus

The clinical progression of diabetes can be understood in stages.

Normoglycemia

In this stage, glucose regulation is normal. No abnormality of glycemia is detected, even when an oral glucose tolerance test is performed.

Impaired Glucose Regulation

This includes abnormalities such as impaired fasting glucose or impaired glucose tolerance. These patients may not yet meet the criteria for diabetes, but they are at increased risk of developing diabetes in the future.

Diabetes Mellitus

At this stage, there is established hyperglycemia. It may be detected by fasting blood glucose, random blood glucose with symptoms, oral glucose tolerance testing, or HbA1c.

Pathophysiology of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.

In the early stages, the body compensates for insulin resistance by increasing insulin production. This compensatory hyperinsulinemia may maintain normal blood glucose for some time. However, as beta-cell function progressively declines, the pancreas becomes unable to produce sufficient insulin to meet the body’s needs.

This progression may move from normal glucose regulation to impaired glucose tolerance and eventually to established diabetes.

The disease is both polygenic and multifactorial. Genetic susceptibility interacts with environmental and lifestyle factors such as obesity, poor diet, and physical inactivity. These factors contribute to both insulin resistance and beta-cell failure.

Insulin Resistance

Insulin resistance is a state in which a given concentration of insulin produces a less-than-expected biological effect.

In Type 2 Diabetes Mellitus, insulin resistance is central to disease development. The body’s tissues, especially skeletal muscle, liver, and adipose tissue, become less responsive to insulin. As a result, glucose uptake is reduced, hepatic glucose production increases, and blood glucose rises.

Causes and contributors to insulin resistance include:

Aging
Obesity
Reduced physical activity
Increased production of insulin antagonists
Stress states such as trauma, surgery, severe infection, uremia, and liver cirrhosis
Endocrine disorders such as Cushing syndrome and acromegaly
Medications such as glucocorticoids, cyclosporine, niacin, and protease inhibitors

Risk Factors for Type 2 Diabetes Mellitus

Important risk factors include:

Family history of diabetes, especially in a parent or sibling
Obesity, particularly BMI above 25 kg/m²
Habitual physical inactivity
Previous impaired fasting glucose or impaired glucose tolerance
History of gestational diabetes mellitus
Previous delivery of a baby weighing more than 4 kg
Hypertension
Dyslipidemia, including low HDL cholesterol or high triglycerides
Polycystic ovary syndrome
Acanthosis nigricans
History of vascular disease

These risk factors should prompt clinicians to screen early, counsel patients on lifestyle modification, and monitor for complications.

Clinical Features

Patients with diabetes may present with classic symptoms of hyperglycemia. These include:

Polyuria
Polydipsia
Polyphagia
Weight loss
Fatigue
Blurred vision
Recurrent infections
Delayed wound healing

In Type 1 Diabetes, symptoms may be more abrupt and severe, sometimes presenting with diabetic ketoacidosis. In Type 2 Diabetes, symptoms may be gradual, and many patients may be diagnosed incidentally during routine testing or when complications have already developed.

A diagnosis of Diabetes Mellitus can be made based on glucose abnormalities. The diagnostic criteria include:

Fasting plasma glucose of 126 mg/dL or higher, equivalent to 7.0 mmol/L or higher
Random venous plasma glucose of 200 mg/dL or higher, equivalent to 11.1 mmol/L or higher, especially in the presence of symptoms
Two-hour plasma glucose of 200 mg/dL or higher after an oral glucose tolerance test
HbA1c of 6.5% or higher

In the absence of unequivocal hyperglycemia, abnormal results should generally be confirmed by repeat testing.

Pre-Diabetes

Pre-diabetes refers to glucose levels that are above normal but not yet within the diabetic range.

It includes:

Impaired fasting glucose
Impaired glucose tolerance
HbA1c levels below the diabetic threshold but above normal

Pre-diabetes is clinically important because it identifies patients at increased risk of developing Type 2 Diabetes Mellitus and cardiovascular disease. It is also a window of opportunity for preventive intervention through lifestyle modification.

Investigations

Important investigations in diabetes include:

Random blood sugar
Fasting blood sugar
Oral glucose tolerance test
HbA1c
Urine glucose testing
Urine ketone testing
Blood ketone testing where diabetic ketoacidosis is suspected
C-peptide testing where assessment of endogenous insulin secretion is needed

HbA1c is useful because it reflects average blood glucose over the previous two to three months. It is widely used to assess long-term glycemic control.

C-peptide is useful because it reflects endogenous insulin production. It is secreted by pancreatic beta cells in equal amounts to insulin but is not present in synthetic insulin. This makes it useful in insulin-treated patients where direct insulin measurement may not distinguish endogenous from exogenous insulin.

Goals of Management

The goals of diabetes management include:

Relief of symptoms
Achievement of good glycemic control
Prevention or delay of microvascular complications
Reduction of macrovascular risk
Control of associated cardiovascular risk factors
Improvement of quality of life
Prevention of acute metabolic emergencies such as diabetic ketoacidosis and hyperosmolar hyperglycemic state

Common therapeutic targets include:

HbA1c below 7% for many patients
Preprandial plasma glucose between 90 and 130 mg/dL
Peak postprandial plasma glucose below 180 mg/dL
LDL cholesterol below 100 mg/dL
Triglycerides below 150 mg/dL
HDL cholesterol above 40 mg/dL

Targets should be individualized according to age, comorbidities, risk of hypoglycemia, life expectancy, and patient-specific factors.

General Management

Management of diabetes includes:

Lifestyle modification
Dietary intervention
Physical activity
Weight reduction where appropriate
Oral anti-diabetic drugs
Injectable therapies including insulin and GLP-1 receptor agonists
Cardiovascular risk reduction
Patient education and long-term follow-up

Diabetes management is lifelong. Patients require continuous monitoring, education, and adjustment of therapy.

Dietary and Lifestyle Modification

Dietary management is a foundation of diabetes care.

A simple plate model can be used to guide meal planning. The plate should emphasize vegetables and fruits, controlled portions of carbohydrates such as rice, pasta, bread, or potatoes, and appropriate protein sources such as fish, meat, eggs, or cheese.

Patients should be encouraged to:

Reduce refined sugars
Control carbohydrate portions
Increase fiber intake
Reduce saturated fats
Avoid excessive calories
Engage in regular physical activity
Achieve and maintain a healthy weight
Stop smoking
Limit alcohol intake where relevant

Lifestyle changes are not “small advice”; they are actual treatment. Tablets will not rescue a patient who continues eating like the pancreas is immortal.

Pharmacological Treatment

Drug therapy depends on the type of diabetes, level of glycemic control, comorbidities, and patient-specific factors.

Common classes of anti-diabetic drugs include:

Biguanides such as Metformin
Alpha-glucosidase inhibitors such as Acarbose
DPP-4 inhibitors such as Sitagliptin and Linagliptin
Sulfonylureas such as Glibenclamide and Glimepiride
Meglitinides such as Repaglinide
SGLT2 inhibitors such as Dapagliflozin, Empagliflozin, and Canagliflozin
Thiazolidinediones such as Pioglitazone
GLP-1 receptor agonists
Insulin therapy

Metformin remains a common first-line agent in Type 2 Diabetes Mellitus unless contraindicated. Other agents are added depending on glycemic control, cardiovascular risk, renal status, weight considerations, cost, and availability.

Insulin Therapy

Insulin is essential in Type 1 Diabetes Mellitus and may be required in Type 2 Diabetes Mellitus when oral therapies fail or during periods of acute stress.

Indications for long-term insulin therapy include:

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus with failure of oral hypoglycemic agents

Intermittent indications include:

Type 2 Diabetes during severe infection
Type 2 Diabetes during surgery
Myocardial infarction
Stroke
Diabetic ketoacidosis
Hyperosmolar non-ketotic coma
Pregnancy

Other non-diabetic uses of insulin include management of hyperkalemia and stimulation tests for endocrine disorders such as acromegaly.

Types of Insulin Preparations

Insulin preparations differ in onset, peak, and duration of action.

They include:

Rapid-acting insulin analogues
Short-acting soluble insulin
Intermediate-acting insulin such as NPH
Long-acting insulin preparations
Long-acting insulin analogues such as glargine and detemir

Understanding insulin timing is important to avoid hypoglycemia and to match insulin action with meals and fasting periods.

Side Effects of Insulin

Important side effects include:

Weight gain
Edema
Hypoglycemia
Lipoatrophy at injection sites
Lipohypertrophy at injection sites
Insulin resistance

Injection sites should be rotated to reduce local complications.

SGLT2 Inhibitors

SGLT2 inhibitors are an important class of drugs in the management of Type 2 Diabetes Mellitus.

They act by inhibiting sodium-glucose co-transporter 2 in the proximal renal tubule. This blocks reabsorption of filtered glucose and increases urinary glucose excretion. The result is lowering of blood glucose through a mechanism that is independent of insulin secretion.

Examples include:

Dapagliflozin
Empagliflozin
Canagliflozin

These drugs are commonly recognized by the “-gliflozin” ending.

Dapagliflozin

Dapagliflozin is an SGLT2 inhibitor used in the management of Type 2 Diabetes Mellitus. It reduces blood glucose by promoting urinary glucose loss.

Available formulations in the uploaded content include Dapagliflozin alone and combinations with Metformin, including:

Dapagliflozin 5 mg
Dapagliflozin 10 mg
Dapagliflozin with extended-release Metformin 500 mg
Dapagliflozin with extended-release Metformin 1000 mg

Combination therapy with Metformin is useful because it targets diabetes through complementary mechanisms: Metformin reduces hepatic glucose production and improves insulin sensitivity, while Dapagliflozin increases renal glucose excretion.

Benefits of SGLT2 Inhibitors

Major advantages include:

Weight loss
Low risk of hypoglycemia when used alone
Cardiovascular benefit in selected high-risk patients
Reduction in heart failure hospitalization
Slowing progression of nephropathy in appropriate patients
Blood pressure reduction through osmotic diuresis and natriuresis

SGLT2 inhibitors are particularly important in patients with Type 2 Diabetes Mellitus who have established cardiovascular disease, heart failure, or chronic kidney disease, where appropriate.

Proposed Benefits in Heart Failure

SGLT2 inhibitors have benefits beyond glucose lowering.

Their proposed mechanisms in heart failure include:

Osmotic diuresis
Natriuresis
Reduction in preload
Reduction in afterload
Improved myocardial energetics
Reduction in myocardial stress
Possible metabolic and anti-inflammatory effects
Reduction in progression of nephropathy

This explains why SGLT2 inhibitors are now clinically important not only in diabetes care but also in cardiovascular and renal protection.

Contraindications and Cautions

SGLT2 inhibitors should be used carefully in patients with impaired renal function.

The uploaded course material highlights that initiation is generally contraindicated when estimated GFR is below 30 mL/min/1.73 m².

They should also be used cautiously in patients at risk of dehydration, recurrent genital infections, ketoacidosis, or acute kidney injury.

Side Effects of SGLT2 Inhibitors

Common and important adverse effects include:

Genital fungal infections
Urinary tract infections
Osmotic diuresis
Volume depletion
Acute kidney injury, especially where hypovolemia occurs
Euglycemic diabetic ketoacidosis
Possible risk of lower limb amputation and fractures with Canagliflozin

Patients should be educated to report symptoms such as genital itching, dysuria, dizziness, vomiting, abdominal pain, or unexplained weakness.

Guideline-Based Use of SGLT2 Inhibitors

SGLT2 inhibitors are especially useful in Type 2 Diabetes Mellitus patients with:

Established atherosclerotic cardiovascular disease
Indicators of high cardiovascular risk
Heart failure
Chronic kidney disease
Need for weight reduction
Need to avoid hypoglycemia

In patients with Type 2 Diabetes and heart failure, an SGLT2 inhibitor with proven heart failure benefit should be considered where not contraindicated.

In patients with chronic kidney disease, SGLT2 inhibitors may be preferred because of their renal protective effects, provided the renal function is within the acceptable range for use.

Complications to Prevent

Good diabetes management aims to prevent both microvascular and macrovascular complications.

Microvascular complications include:

Diabetic retinopathy
Diabetic nephropathy
Diabetic neuropathy

Macrovascular complications include:

Coronary artery disease
Stroke
Peripheral arterial disease

Cardiovascular risk factor control is therefore not optional. Treating glucose while ignoring blood pressure, lipids, smoking, and weight is like mopping the floor while the tap is still open.

Patient Education

Patients should understand:

Diabetes is lifelong
Good control reduces complications
Medication adherence matters
Diet and exercise are part of treatment
Regular monitoring is necessary
Foot care is important
Symptoms of hypoglycemia should be recognized
Symptoms of ketoacidosis should be recognized
SGLT2 inhibitors can cause genital infections and rarely ketoacidosis
Follow-up is essential even when symptoms improve

Patients on SGLT2 inhibitors should be advised to maintain hydration and seek medical care if they develop severe illness, vomiting, reduced oral intake, or symptoms suggestive of ketoacidosis.

Type 2 Diabetes Mellitus is mainly driven by insulin resistance and progressive beta-cell failure.
Most patients with Type 2 Diabetes have relative, not absolute, insulin deficiency.
Diabetes diagnosis can be made using fasting glucose, random glucose with symptoms, OGTT, or HbA1c.
HbA1c reflects average glycemic control over the previous two to three months.
Lifestyle modification is not decoration; it is core treatment.
Insulin is mandatory in Type 1 Diabetes and may become necessary in Type 2 Diabetes when oral agents fail or during acute illness.
SGLT2 inhibitors lower glucose by increasing urinary glucose excretion through inhibition of renal glucose reabsorption.
Dapagliflozin is useful in Type 2 Diabetes and has important benefits in selected patients with cardiovascular, heart failure, or renal risk.
Watch for genital infections, dehydration, acute kidney injury, and euglycemic diabetic ketoacidosis in patients on SGLT2 inhibitors.
Diabetes care must target glucose, blood pressure, lipids, weight, kidney function, cardiovascular risk, and patient education.